Page last updated: 2024-09-03

mk 0663 and Neurodegenerative Diseases

mk 0663 has been researched along with Neurodegenerative Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beswick, PJ; Bingham, S; Bountra, C; Carter, MC; Chambers, LJ; Chessell, IP; Clayton, NM; Collins, SD; Corfield, JA; Gleave, RJ; Green, RH; Hartley, CD; Kleanthous, S; Lambeth, PF; Lucas, FS; Mathews, N; Naylor, A; Page, LW; Payne, JJ; Pegg, NA; Price, HS; Skidmore, J; Stevens, AJ; Stocker, R; Stratton, SC; Stuart, AJ; Swarbrick, ME; Wiseman, JO1
Ghosh, T; Sil, S1

Other Studies

2 other study(ies) available for mk 0663 and Neurodegenerative Diseases

ArticleYear
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15

    Topics: Amines; Animals; Brain; Chemistry, Pharmaceutical; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Ethers; Humans; Inflammation; Inhibitory Concentration 50; Mice; Molecular Structure; Neurodegenerative Diseases; Pyrimidines; Rats; Sulfones

2009
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
    Journal of neuroimmunology, 2016, Feb-15, Volume: 291

    Topics: Alzheimer Disease; Analysis of Variance; Animals; Cognition Disorders; Colchicine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Etoricoxib; Injections, Intraventricular; Male; Maze Learning; Neurodegenerative Diseases; Plaque, Amyloid; Pyridines; Rats; Sulfones; Time Factors

2016